Article Per Year (5 Year)
p-Index From 2021 - 2026
4.586
P-Index
This Author published in this journals
All Journal Farmasains : Jurnal Farmasi dan Ilmu Kesehatan Jurnal Kedokteran Brawijaya Jurnal Farmasi Sains dan Terapan (Journal of Pharmacy Science and Practice) Media Farmasi : Jurnal Ilmu Farmasi (Journal Of Pharmaceutical Science) Jurnal Kesehatan Jurnal Farmasi Klinik Indonesia Pharmacon MPI (Media Pharmaceutica Indonesiana) Pharmascience JURNAL FARMASI DAN ILMU KEFARMASIAN INDONESIA Pharmasipha PHARMACY: Jurnal Farmasi Indonesia (Pharmaceutical Journal of Indonesia) JFIOnline Pharmaceutical Journal of Indonesia JFM (Jurnal Farmasi Malahayati) JURNAL FARMASIMED (JFM) Majalah Farmasetika Jurnal Ilmiah Farmasi Farmasyifa Budapest International Research in Exact Sciences (BirEx Journal) Hubungan Tingkat Pengetahuan Petugas Pengelola Obat dengan Tingkat Ketersediaan Obat Di Puskesmas Kota Malang Jurnal Farmasi dan Sains Indonesia (JFSI) Indonesian Journal of Pharmaceutical Education Journal of Global Pharma Technology Journal of Tropical Pharmacy and Chemistry Jurnal Sains dan Kesehatan Jurnal Farmasi Sains dan Terapan (Journal of Pharmacy Science and Practice) Folia Medica Indonesiana
Didik Hasmono
Department Of Clinical Pharmacy, Faculty Of Pharmacy, Universitas Airlangga
Agriculture, Biological Sciences & Forestry Biochemistry, Genetics & Molecular Biology Chemistry Civil Engineering, Building, Construction & Architecture Education Environmental Science Health Professions Immunology & microbiology Materials Science & Nanotechnology Medicine & Pharmacology Neuroscience Nursing Physics Public Health Transportation Other

Published : 73 Documents Claim Missing Document
Claim Missing Document
Check
Articles

Found 3 Documents
Search
Journal : Pharmacon

 1 
Tinjauan Azitromisin Pada Penyakit Virus Korona 2019 (COVID-19) Donsu, Yosefien Christania; Hasmono, Didik
Pharmacon: Jurnal Farmasi Indonesia Vol 17, No 2 (2020)
Publisher : Universitas Muhammadiyah Surakarta

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.23917/pharmacon.v17i2.12359

Abstract

Coronavirus disease 2019 (COVID-19) is an infectious disease caused by SARS-CoV-2. The World Health Organization has declared this disease a pandemic, where the scale of the spread of the disease occurs globally throughout the world. Currently, there is no validated pharmacological treatment for COVID-19 disease, and is still in the clinical trial stage. Azithromycin in conjunction with hydroxychloroquine or chloroquine has been proposed as a treatment that can improve the prognosis of COVID-19. This review aims to describe the mechanism of action and effectiveness of azithromycin in the treatment of COVID-19 patients. The review of the article literature was carried out through internet searches by accessing the database from google scholar, PubMed, and science direct sites. The inclusion criteria in this review are articles using azithromycin in clinical trials and COVID-19 therapy which were published from December 2019 to October 2020. Azithromycin is a macrolide antibacterial and is based on studies having antiviral and immunomodulatory effects. The use of azithromycin can lower viral load when added to hydroxychloroquine in COVID-19 patients based on small-scale clinical studies. Azithromycin used with hydroxychloroquine or chloroquine has shown good results, although it raises concerns about the risk of increased side effects of prolonged QT interval so that monitoring of the heart is needed and proven in a larger number of COVID-19 patients. The decision to use azithromycin must take into account the potential benefits and risks, evaluating the possibility of the drug being more effective than the risks to the patient.
Tinjauan Azitromisin Pada Penyakit Virus Korona 2019 (COVID-19) Yosefien Christania Donsu; Didik Hasmono
Pharmacon: Jurnal Farmasi Indonesia Vol 17, No 2 (2020)
Publisher : Universitas Muhammadiyah Surakarta

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.23917/pharmacon.v17i2.12359

Abstract

Coronavirus disease 2019 (COVID-19) is an infectious disease caused by SARS-CoV-2. The World Health Organization has declared this disease a pandemic, where the scale of the spread of the disease occurs globally throughout the world. Currently, there is no validated pharmacological treatment for COVID-19 disease, and is still in the clinical trial stage. Azithromycin in conjunction with hydroxychloroquine or chloroquine has been proposed as a treatment that can improve the prognosis of COVID-19. This review aims to describe the mechanism of action and effectiveness of azithromycin in the treatment of COVID-19 patients. The review of the article literature was carried out through internet searches by accessing the database from google scholar, PubMed, and science direct sites. The inclusion criteria in this review are articles using azithromycin in clinical trials and COVID-19 therapy which were published from December 2019 to October 2020. Azithromycin is a macrolide antibacterial and is based on studies having antiviral and immunomodulatory effects. The use of azithromycin can lower viral load when added to hydroxychloroquine in COVID-19 patients based on small-scale clinical studies. Azithromycin used with hydroxychloroquine or chloroquine has shown good results, although it raises concerns about the risk of increased side effects of prolonged QT interval so that monitoring of the heart is needed and proven in a larger number of COVID-19 patients. The decision to use azithromycin must take into account the potential benefits and risks, evaluating the possibility of the drug being more effective than the risks to the patient.
Studi Penggunaan Obat Anti Tuberkulosis (OAT) Tahap Lanjutan pada Pasien Baru BTA Positif Tista Ayu Fortuna; Hidajah Rachmawati; Didik Hasmono; Hidayah Karuniawati
Pharmacon: Jurnal Farmasi Indonesia Vol 19, No 1 (2022)
Publisher : Universitas Muhammadiyah Surakarta

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.23917/pharmacon.v19i1.17907

Abstract

Tuberculosis is an infectious disease caused by Mycobacterium tuberculosis. Tuberculosis will cause pain and death if not treated properly. OAT (Antituberculosis Drugs) is a treatment for tuberculosis patients. OAT has different dosage regimens and types of drugs. Treatment of TB patients consists of two phases (intensive and continuation phases). The continuation phase was at to kill dormant bacteria to prevent recurrence in patients. The purpose of this study was to determine and evaluate the pattern of using OAT in patients newly diagnosed rwith smear-positive at the continuation phase. This study is an observational descriptive study with results showing that the pattern of using OAT-KDT in patients was 89% and OAT-Separated was 11%. The pattern of using the OAT-KDT dose was 1x3 2KDT tablets. Another combination of antibiotics given to the patient is cotrimoxazole at a dose of 1x960mg. The side effect of OAT is an increase in serum transaminase and nausea each with a percentage of 23%. Based on the research, it can be concluded that the pattern of using OAT in Tuberculosis patients has followed the guidelines for the management of Tuberculosis treatment.
Co-Authors Adinugraha Amarullah Aghnia Fuadatul Inayah Agriawan Sudirman Agriawan Sudirman Agus Sunarko Agus Sunarko Alfa Frista Arta Alfin Giovani Amarullah, Adinugraha Andilusia, Sindy Ardianty, Nonie Arina Dery Puspitasari Aryani, Dhita Aryani, Dhita Evi Astutik, Widi Atika Putri Kusumaningtyas Atmajani, Wanudya Awdisma, Wien Maryati Ayumuyas, Nur Palestin Ayumuyas, Nur Palestin Ayunda Nur Hidayatiningsih Bambang Sidharta Binti Muzayyanah Budi Suprapti Budiatin, Aniek Setiya Bura, Ursula Dua Klowe Chrysnanda Maryska Claudia Tiffany Dea Ayu Nabilah Dinda Monika Nusantara Ratri Dini Setiya Praja Dini Setiya Praja, Dini Setiya Donsu, Yosefien Christania Elisabeth Kasih Fadlilah, Umul Firandi, Adelia Ganesha T Trengginas Giovani, Alfin Hadiyanti, Nur Hanum, Putri Safitri Hariyati, Fera Hariyati, Fera Hartono, Ruddy Hasbi As-Shiddiq Hendra Yadi Heni Pujiastuti Hidajah Rachmawati Hidajah Rachmawati Hidayah Karuniawati Hidayah, Ana Nurlaili IGD Ugrasena Ilfi Hanna, Az Zahra Insyirah Idris, Anissah Irianto, Jimmy Setiawan Irsan Fahmi Almuhtarihan Irsan Fahmi Almuhtarihan Ismawati Isparnadi, Erwien Issaura, Issaura Jenggo Suwarko Joko Semedi Junaidi Khotib Khairil Armal Kuntaman Kuntaman Kusumaningrum , Yunita Dyah Kusumaningtyas, Atika Putri Lilik Yusetyani Lilik Yusetyani Ma'rifah, Nurul Machin, Abdulloh Mahardian Rahmadi Mareta Rindang Andarsari Maria Angelia Yoshida Meiliana, Made Laksmi Meo, Maria Lettisia Mia Melinda Mohammad Saiful Islam Mohammad Saiful Islam, Mohammad Saiful Mohammad Subhan Mohammad Subhan Mohammad Subhan Mohammad Subkhan Muhammad Nashrullah Muktamiroh Muktamiroh Muzayyanah, Binti Nadriatul Utami Nadriatul Utami Nailis Syifa Ni Made Eravikania Putri Darmawan Nun Zairina, Nun Nur Hadiyanti Nuraida Wisudani Nurfausiah, Nurfausiah Nurmainah Nurmainah Nurul Ma'rifah Paulus Sugianto Pharmasinta Putri Hapsari Pramadani, Yana Puri Safitri Hanum Puspitasari, Diny Putri Nurhidayah, Eka Ramdani, Dewi Retna Dwi Puspitarini Rino Wahyudi, Rino Risa Septinia Rizki Lisya Nugraha Roni Subagyo RR. Ella Evrita Hestiandari Ruddy Hartono Ruddy Hartono Ruddy Hartono Ruddy Hartono Ruhaya Fitrina, Ruhaya Samirah Samirah Sandra J. Parambang Sandra, Pipit Semedi, Joko Sendi Lia Yunita Setiawan, Landia Siti Surdijati Siti Surdijati, Siti Sofiati Diah Baisuni Subagyo, Roni Suharjono Suharjono, Suharjono Sumarno Sumarno Syifa', Nailis Syifa, Nailis' Tanasy, Marledy Taufiqur Rahman, Taufiqur Thayyib, Muqoddar Tista Ayu Fortuna Trengginas, Ganesha T Ugrasena, IGD Ulfa Syafli Nosa Usman Hadi Utami, Nadriatul Wardhani, Firdha Aprillia Wardhani, Hety Setya Widi Astutik Widi Astutik Wien Maryati Awdisma Wiranata, I Made Wisudani, Nuraida Worotikan, Natania Imanuella Yosefien Christania Donsu Yudi Agung Wibisono Yudistira Nurrizky Grahitaning Putra Rohmaana Yulistiani Yulistiani Yulistiani Yulistiani, Yulistiani Yulistiani, . Yuni, Santi Eka Yuni, Santi Eka